First Patient Dosed in Phase 1b Trial of Experimental Myelofibrosis Drug
According to a press release from biotechnology company Forbius (Formation Biologics Inc.), the first patient in the Company's phase 1b trial of experimental myelofibrosis (MF) drug AVID200 has successfully received…